BPS Solid Organ Transplantation Pharmacy Certification Examination Practice Test
Solid organ transplant pharmacy addresses medication management before and after kidney, liver, and heart transplantation. The subject involves immunosuppressive regimens, allograft monitoring, infection prevention and treatment, and medication-related complications. Clinical decisions must account for graft function, changing renal clearance, drug interactions, and the risks of suppressing immune responses while preserving transplant function.
Exam overview
About the BPS Solid Organ Transplantation Pharmacy Certification Examination Exam
Transplant pharmacists assess immunosuppressant exposure and toxicity, interpret therapeutic drug monitoring, and recognize interactions that may alter calcineurin inhibitor or other immunosuppressant concentrations. They evaluate medication dosing as graft function changes and identify complications such as leukopenia, post-transplant hyperglycemia, infection, and possible rejection. Patient-care tasks also include reviewing vaccine safety during immunosuppression, selecting antimicrobial therapy with interaction risks in mind, and considering how tests such as donor-derived cell-free DNA contribute to allograft assessment. Organ-specific evaluation may involve interpreting kidney function or supporting assessment of liver biliary and vascular complications. Strong practice requires connecting clinical findings and laboratory data to medication recommendations, monitoring plans, and coordinated care with the transplant team.
Sample Practice Questions
Review a selection from this exam's published US Practice Tests practice bank.
A kidney transplant recipient is prescribed an extended course of a proton pump inhibitor. Which potential issue is reasonable to consider when reviewing the regimen?
Show answer
Correct answer: AAcid-suppressing agents can affect the exposure of selected drugs, and the relevance depends on the particular medication combination and patient. The regimen should be reviewed for interactions and monitored as appropriate; a universal dose change or discontinuation is not justified.
A kidney transplant recipient taking maintenance immunosuppression is scheduled to receive a live attenuated varicella vaccine because of absent varicella immunity. What is the safest general recommendation?
Show answer
Correct answer: BLive attenuated vaccines can cause vaccine-strain disease in substantially immunosuppressed patients and are generally avoided after transplantation during significant immunosuppression. The transplant team can consider exposure prevention and whether vaccination is appropriate at a different time or under specific circumstances.
A kidney transplant recipient is being evaluated for donor-derived cell-free DNA testing. What is the principal role of this test in allograft monitoring?
Show answer
Correct answer: BDonor-derived cell-free DNA can rise when a transplanted organ is injured and may support noninvasive surveillance or evaluation. It is not specific for rejection, does not identify the cause of injury, and does not universally replace biopsy or clinical assessment.
A transplant recipient taking chronic immunosuppression is prescribed an inactivated influenza vaccine. Which statement is most accurate?
Show answer
Correct answer: AInactivated influenza vaccine is generally used for solid organ transplant recipients; live attenuated influenza vaccine is typically avoided in substantially immunocompromised patients. Vaccine response may be reduced, and vaccination does not replace other preventive measures.
A transplant recipient taking mycophenolate develops leukopenia. Which general management principle is most appropriate?
Show answer
Correct answer: AMycophenolate can contribute to cytopenias, but leukopenia may also reflect infection or other medications and conditions. The finding should be evaluated and any immunosuppressant adjustment coordinated with the transplant team to balance safety and rejection risk.
A patient with a functioning transplanted kidney is being considered for a medication cleared primarily by the kidneys. Which information is most useful for assessing whether a dose adjustment may be needed?
Show answer
Correct answer: AFor drugs with substantial renal elimination, dosing decisions commonly depend on current kidney function rather than transplant status or transplant date alone. The appropriate renal-function estimate and drug-specific dosing guidance should be used.
A heart transplant recipient taking tacrolimus has a fasting glucose of 240 mg/dL on repeated measurements several months after transplant. Which adverse effect should be considered?
Show answer
Correct answer: ATacrolimus can impair pancreatic beta-cell function and contribute to hyperglycemia and post-transplant diabetes mellitus. Repeated elevated fasting glucose warrants clinical assessment and management rather than being dismissed as assay interference.
How to use this practice test
Work through the free BCTXP practice questions in sessions of up to 20 randomly selected items from the 50-question bank. Use the displayed results after each session to identify missed decisions, such as interaction management, immunosuppression safety, or organ-function-based dosing, then revisit those concepts before another session.
Preparation tips
- For immunosuppressant cases, trace how a new medication or infection could change drug exposure, toxicity, or rejection risk.
- Practice evaluating medication doses against current graft function, especially when renal clearance may change after kidney transplantation.
- Compare vaccine types and infection risks in patients receiving chronic immunosuppression, including the safety concern with live attenuated vaccines.
- Review transplant-related adverse effects such as mycophenolate-associated leukopenia and immunosuppressant-associated hyperglycemia, linking findings to monitoring and management decisions.
- Distinguish the roles of allograft monitoring tests and organ-specific imaging when interpreting a transplant clinical scenario.